- Home
- POM vs OTLK Comparison
POM vs OTLK Comparison
Compare POM & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POM | OTLK |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8M | 38.7M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | POM | OTLK |
|---|---|---|
| Price | $0.30 | $0.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 1.3M | ★ 13.6M |
| Earning Date | 12-03-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,210,721.00 | $1,413,535.00 |
| Revenue This Year | N/A | $2,048.59 |
| Revenue Next Year | N/A | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.13 | N/A |
| 52 Week Low | $0.26 | $0.50 |
| 52 Week High | $6.43 | $3.39 |
Technical Indicators
Market Signals| Indicator | POM | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 24.74 |
| Support Level | N/A | $0.50 |
| Resistance Level | N/A | $0.65 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 2.92 |
Price Performance
Historical ComparisonAbout POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.